Efficacy of First MTPJ Arthrodesis as a Treatment in Hallux Rigidus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-22

Study Completion Date

2029-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomised, controlled trial will be performed by allocating 40 years or older patients with symptomatic hallux rigidus to arthrodesis or watchful waiting group in a ratio of 1:1. Our primary outcome will be pain during walking, assessed by the 0-10 Numeric Rating Scale (NRS) at one year after randomisation. Our secondary outcomes will be pain in rest (NRS), physical function (MOXFQ), patient satisfaction in terms of Patient-accepted Symptom State (PASS), health-related quality of life (EQ-5D-5L), activity level (The Foot and Ankle Ability Measure Sports subscale), use of analgesics or orthoses and rate of complications. Our null hypothesis is that there will be no difference between arthrodesis and watchful waiting in treatment of hallux rigidus. Our primary analysis will be done using intention-to-treat principle.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Synthetic Cartilage Implant Versus Interposition Arthroplasty in Hallux Rigidus Treatment: A Randomized Clinical Trial

NCT05518721

Hallux Rigidus

WITHDRAWN NA

Surgical Treatment for Great Toe Arthritis

NCT03935880

Hallux Rigidus

TERMINATED NA

Surgical Treatment for Hallux Rigidus

NCT01048450

Hallux Limitus Hallux Rigidus

COMPLETED NA

Operative Versus Non-operative Treatment for Mild to Moderate Hallux Valgus Deformity

NCT06114043

Hallux Valgus Deformity

RECRUITING NA

Arthroscopic Assisted Lateral Soft Tissue Release for Hallux Valgus

NCT04088214

Hallux Valgus Hallux Valgus and Bunion

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hallux Rigidus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

A randomised, controlled trial will be performed by allocating 40 years or older patients with symptomatic hallux rigidus to arthrodesis or watchful waiting group in a ratio of 1:1.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

To avoid biased interpretation of the trial data, blinded data interpretation will be used in the reporting of the results of this trial (70). Before accessing the primary outcome data, the writing committee will record a 'Background assumptions' document containing our definition of MID of the outcome measures, and a brief summary of the key statistical analysis used in the evaluation of the outcome data. The document will be signed by the members of the writing committee and published as an appendix to the primary publication.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arthrodesis

MTPJ I Arthrodesis

Group Type ACTIVE_COMPARATOR

Arthrodesis

Intervention Type PROCEDURE

MTPJ I arthrodesis

Watchful waiting

No intervention, patient information leaflet

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Arthrodesis

MTPJ I arthrodesis

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 40 years or over
* Diagnosis of hallux rigidus: Persistent pain on movement of the first MTPJ AND Osteoarthritic first MTPJ in plain X-rays
* Duration of symptoms ≥1 year
* Pain-NRS during walking of 4 or more on a scale 0-10 (higher is worse)
* No substantial pain in other joints of the foot in clinical examination
* Willingness to accept both treatment options
* Ability to understand trial information and answer outcome assessments in Finnish
* Signed informed consent

Exclusion Criteria

* ASA\* physical status classification level III or higher
* Patients with weak co-operation (dementia, schizophrenia, etc.)
* Patients with neuropathy, i.e. unable to feel 10g monofilament pressure in less than 8 out of 10 standard testing sites
* Active bacterial infection or ulcer of the lower limb
* Diabetes mellitus with insulin treatment
* Diabetes mellitus and GHb-A1C \>64 mmol/mol (regardless of treatment)
* History of rheumatoid arthritis, gout or other inflammatory arthritis of the foot
* Hallux valgus angle \>15° in weight-bearing X-ray
* Hallux varus in weight-bearing X-ray
* Large bone cysts in X-ray probably requiring bone grafting in surgery
* Pain in passive manipulation of ipsilateral first toe IP joint
* Patients with severe circulatory disorder of the lower limb: absence of palpable pulses in the foot (both dorsalis pedis artery and tibialis posterior artery)
* History of surgery of the foot in question
* Neuropathic pain of the foot in question (i.e., use of neuropathic analgesics)
* Activity limiting symptoms from an earlier fracture or ligament injury of the foot
* Patient is not willing to accept the operation within the planned time limits (3 to 12 weeks post-randomisation)

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No